$2.44T
Total marketcap
$110.05B
Total volume
BTC 49.73%     ETH 16.77%
Dominance

UCB SA UCB.BR Stock

108.55 EUR {{ price }} 1.924885% {{change_pct}}%
COUNTRY
Belgium
Exchange
Brussels
Market Cap
20.59B EUR
LOW - HIGH [24H]
106.55 - 109.4 EUR
VOLUME [24H]
419.67K EUR
{{ volume }}
P/E Ratio
61.67
Earnings per share
1.76 EUR

UCB SA Price Chart

UCB SA UCB.BR Financial and Trading Overview

UCB SA stock price 108.55 EUR
Previous Close 84.8 EUR
Open 85 EUR
Bid 0 EUR x 0
Ask 0 EUR x 0
Day's Range 85 - 85.5 EUR
52 Week Range 66.62 - 88.8 EUR
Volume 9.12K EUR
Avg. Volume 253.01K EUR
Market Cap 16.3B EUR
Beta (5Y Monthly) 0.352107
PE Ratio (TTM) 39.850464
EPS (TTM) 1.76 EUR
Forward Dividend & Yield 1.33 (1.55%)
Ex-Dividend Date April 28, 2023
1y Target Est 98.9 EUR

UCB.BR Valuation Measures

Enterprise Value 17.87B EUR
Trailing P/E 39.850464
Forward P/E 17.158955
PEG Ratio (5 yr expected) 3.26
Price/Sales (ttm) 2.9921114
Price/Book (mrq) 1.7838392
Enterprise Value/Revenue 3.28
Enterprise Value/EBITDA 15.702

Trading Information

UCB SA Stock Price History

Beta (5Y Monthly) 0.352107
52-Week Change 8.02%
S&P500 52-Week Change 20.43%
52 Week High 88.8 EUR
52 Week Low 66.62 EUR
50-Day Moving Average 84.86 EUR
200-Day Moving Average 77.84 EUR

UCB.BR Share Statistics

Avg. Volume (3 month) 253.01K EUR
Avg. Daily Volume (10-Days) 212.36K EUR
Shares Outstanding 189.6M
Float 120.15M
Short Ratio N/A
% Held by Insiders 38.03%
% Held by Institutions 39.68%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 1.33
Trailing Annual Dividend Yield 1.56%
5 Year Average Dividend Yield 153.00%
Payout Ratio 0.6047
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 7.67%
Operating Margin (ttm) 10.99%
Gross Margin 69.26%
EBITDA Margin 20.89%

Management Effectiveness

Return on Assets (ttm) 2.48%
Return on Equity (ttm) 4.81%

Income Statement

Revenue (ttm) 5.45B EUR
Revenue Per Share (ttm) 28.73 EUR
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 3.77B EUR
EBITDA 1.14B EUR
Net Income Avi to Common (ttm) 420M EUR
Diluted EPS (ttm) 2.14
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 946M EUR
Total Cash Per Share (mrq) 4.99 EUR
Total Debt (mrq) 2.9B EUR
Total Debt/Equity (mrq) 32 EUR
Current Ratio (mrq) 1.062
Book Value Per Share (mrq) 47.807

Cash Flow Statement

Operating Cash Flow (ttm) 1.12B EUR
Levered Free Cash Flow (ttm) 749.37M EUR

Profile of UCB SA

Country Belgium
State N/A
City Brussels
Address AllEe de la Recherche, 60
ZIP 1070
Phone 32 2 559 99 99
Website https://www.ucb.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 8108

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Q&A For UCB SA Stock

What is a current UCB.BR stock price?

UCB SA UCB.BR stock price today per share is 108.55 EUR.

How to purchase UCB SA stock?

You can buy UCB.BR shares on the Brussels exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for UCB SA?

The stock symbol or ticker of UCB SA is UCB.BR.

Which industry does the UCB SA company belong to?

The UCB SA industry is Biotechnology.

How many shares does UCB SA have in circulation?

The max supply of UCB SA shares is 189.72M.

What is UCB SA Price to Earnings Ratio (PE Ratio)?

UCB SA PE Ratio is 61.67614000 now.

What was UCB SA earnings per share over the trailing 12 months (TTM)?

UCB SA EPS is 1.76 EUR over the trailing 12 months.

Which sector does the UCB SA company belong to?

The UCB SA sector is Healthcare.

UCB SA UCB.BR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
BEL 20 BFX 3698.82 EUR 4048.18 USD
+1.02
3677.51 EUR 4024.85 USD 3705.76 EUR 4055.77 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1410.69 USD
<0.01
2100.38 AUD 1410.69 USD 2100.38 AUD 1410.69 USD
Euronext 100 Index N100 1467.75 EUR 1606.38 USD
+0.59
1459.81 EUR 1597.69 USD 1467.76 EUR 1606.39 USD
Nasdaq CRD Global Sustainabilit NQCRD 1735.62 USD
0
1715.94 USD 1757.95 USD